Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?

Platinum-based chemotherapy remains the backbone of first-line therapy while immunotherapy is now the standard of care in second-line setting after failure of first-line chemotherapy, as maintenance therapy in patients responding to first-line chemotherapy and in first-line in cisplatin-ineligible PD-L1 positive patients or in those not eligible for any platinum-containing chemotherapy [[32], [68]]. The EMA granted approval for this drug as therapy of advanced urothelial carcinoma patients progressing to platinum-based chemotherapy or not eligible for cisplatin-based chemotherapy. The new molecular classification of urothelial carcinoma in six subtypes with different prognosis and therapy response is paving the way for the tailored treatment of urothelial carcinoma patients. [Extracted from the article]